Breyer, Johannes and Wirtz, Ralph M. and Otto, Wolfgang and Erben, Philipp and Worst, Thomas S. and Stoehr, Robert and Eckstein, Markus and Denzinger, Stefan and Burger, Maximilian and Hartmann, Arndt (2018) High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. CANCER IMMUNOLOGY IMMUNOTHERAPY, 67 (3). pp. 403-412. ISSN 0340-7004, 1432-0851
Full text not available from this repository. (Request a copy)Abstract
Introduction and objectives Checkpoint inhibition has emerged as new therapeutic option in muscle-invasive bladder cancer. The objective of the present study was to evaluate the prognostic role of PD1 and PDL1 expression in non-muscle-invasive bladder cancer (NMIBC) and establish an objective measuring method using RNA quantification. Materials and methods We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder. mRNA expression of PD1, PDL1 and CD3 was measured by single step RT-qPCR and correlated to clinicopathological parameters, recurrence-free survival (RFS), progression-free survival (PFS) and carcinoma-specific survival (CSS). Results We have analyzed 334 patients with NMIBC at stage pT1 for mRNA analysis. Data from 296 patients (79% male, median age: 72 years) could be used. Spearman correlation revealed significant associations between mRNA expressions of PD1/PDL1 (rho: 0.6024, p < 0.0001), CD3/PDL1 (rho: 0.5728, p < 0.0001) and CD3/PD1 (rho: 0.7005, p < 0.0001). Kaplan-Meier analysis revealed that high PDL1 mRNA expression (>= 33.83) is a favorable prognostic factor with regard to better RFS (p = 0.0018), PFS (p = 0.021) and CSS (p = 0.012). Multivariate Cox-regression analysis proved PDL1 expression to be an independent prognosticator for RFS [HR 0.48 (0.31-0.72), p = 0.0005], PFS [HR 0.45 (0.24-0.80), p = 0.0059] and CSS [HR 0.31 (0.13-0.67), p = 0.0021]. Conclusion High mRNA expression of PDL1 predicts improved RFS, PFS and CSS of pT1 NMIBC. Following prospective validation, this objective measurement of PD-L1 might help stratify patients with NMIBC for immunotherapy and identify patients who might benefit from early cystectomy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | UROTHELIAL CARCINOMA; BREAST-CANCER; PD-L1 EXPRESSION; CELL; B7-H1; IMMUNOTHERAPY; ASSOCIATION; RECURRENCE; PD1; PDL1; mRNA; NMIBC; Prognosis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Mar 2020 09:39 |
| Last Modified: | 12 Mar 2020 09:39 |
| URI: | https://pred.uni-regensburg.de/id/eprint/14919 |
Actions (login required)
 |
View Item |
